Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Venture Life Group plc
  6. News
  7. Summary
    VLG   GB00BFPM8908

VENTURE LIFE GROUP PLC

(VLG)
  Report
Delayed London Stock Exchange  -  11:35 2022-12-02 am EST
34.00 GBX    0.00%
12/01FTSE 100 Closes Down 0.2% Amid Drop in Oil-Related Stocks
DJ
12/01Sterling Rises Further Vs Dollar But Depends on US Data
DJ
12/01Venture Life Group Buys HL Healthcare; Shares Surge 19%
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Venture Life : 2021 Annual Report

05/31/2022 | 07:31am EST

VENTURE LIFE GROUP

ANNUAL REPORT & ACCOUNTS 2021

DELIVERINGCONSUMER SELF-CAREGLOBALLY

Strategic Report

Page title

OUR MISSION

INTRO Statement

We are committed to providing innovative and efficacious products for the global self-care market, for people who want to lead a healthier life.

OUR VISION

To become a key trusted global leader in self-care products through our knowledge, expertise and capability.

STRATEGIC REPORT

GOVERNANCE

01

Our Highlights

44

Board of Directors

02

The Year in Review

46

Statement of Corporate Governance

04

Q&A with our Director of

48

Directors' Report

Corporate Development

52

Remuneration Report

06

At a Glance

57

Statement of Directors' Responsibilities

08 Our Products

18

Chair's Statement

FINANCIAL STATEMENTS

20

Our Business Model and Strategy

58

Independent Auditor's Report

22

Our Investment Case

66

Consolidated Statement

23

Key Performance Indicators

of Comprehensive Income

24

Development and Manufacturing

67

Consolidated Statement

26

Chief Executive Officer's Statement

of Financial Position

32

Our ESG Strategy

68

Consolidated Statement

34

Principal Risks and Uncertainties

of Changes in Equity

38

Our Section 172 (1) Statement

69

Consolidated Statement

40

Financial Review

of Cash Flows

70

Notes to the Consolidated Statements

105

Parent Company Balance Sheet

106

Parent Company Statement

of Changes in Equity

107

Notes to the Parent Company

Balance Sheet

IBC

Shareholder Information

For more information visit https://www.venture-life.com

1 Venture Life Group plc Annual Report & Accounts 2021

Strategic Report

Our Highlights

The Group delivered another year of revenue & profit growth despite global challenges and has completed its largest ever acquisition

FINANCIAL

8.9%

+0.9%

REVENUE

GROSS PROFIT

Revenue increased 8.9% to

Gross profit increased 0.9% to

£32.8 million (2020: £30.1 million)

£13 million (2020: £12.8 million)

8.2%

+1.4%

ADJUSTED EBITDA1

PROFIT AFTER TAX

Adjusted EBITDA increased 8.2% to

Profit after tax increased 1.4%

£6.6 million (2020: £6.1 million)

to £2.4 million (2020: £2.4 million)

Report Strategic

10.8%

ADJUSTED EARNINGS PER SHARE 2 Adjusted earnings per share increased 10.8% to 4.94 pence (2020: 4.46 pence)

COMMERCIAL

3.1ppts

GROSS MARGIN

Percentage gross margin decrease 3.1ppts cx ed to 39.6% (2020: 42.7%)

  1. Adjusted EBITDA is EBITDA before deduction of exceptional items and share based payments (see note 31 of financial statements)
  2. Adjusted earnings per share is profit after tax excluding amortisation, exceptional items and share-based payments (see note 31 of financial statements)
  • Two immediately earnings enhancing acquisitions, expected to bring significant growth in revenues and profitability; fully deploying funds raised in late 2020; now integrated
  • Revolving Credit Facility (RCF) in place for up to £50 million, giving significant firepower for further earnings accretive M&A: deployed £9.0 million at 31 December 2021
  • Extended agreement with Bayer Consumer Care AG for BV gel, a women's intimate healthcare product
  • 11 new long-term distribution agreements signed
  • 18 in-market product launches through our international partners
  • 7 approved product registrations, with 12 on-going

Venture Life Group plc

01

Annual Report & Accounts 2021

Strategic Report

The Year in Review

Against a challenging backdrop, 2021 was again, another pivotal year

ACQUISITION OF BBI HEALTHCARE LIMITED

ACQUISITION OF HELSINN

INTEGRATIVE CARE PORTFOLIO (HCIP)

BBI Healthcare Limited (BBI) was acquired on 4 June 2021. This profitable UK based consumer healthcare business, with manufacturing operations in Gnesta, Sweden, brought with it new products in the area of women's health and diabetes management, along with a fast-growing presence in the UK and internationally for its products.

Its innovative Balance Activ® brand for bacterial vaginosis is sold primarily in the UK under this brand, but is also sold internationally through Bayer Consumer Care AG, where Lift™, a measured dose glucose supplement is the fastest growing product of the acquired portfolio, providing a measured dose of glucose by either chewable tablets or a liquid shot.

This acquisition satisfied a number of our key acquisition criteria, bringing an immediately earnings enhancing transaction, along with immediate cost synergies, and the opportunity for revenue expansion and manufacturing synergies. Already fully integrated into the Group, this business significantly increased the size of the Venture Life Group and brought us into two key therapy areas.

  • Purchase consideration £35 million, plus £1 million deferred.
  • Reported revenues from 4 June 2021 to 31 December 2021 were £6.5 million (full year revenues were £10.3 million, growth of 8.4% over previous year)
  • Gross margin for 4 June 2021 to 31 December 2021 of 48.1% (full year gross margin was 47.9%)
  • Immediate post-acquisition cost synergies of £0.9 million (on an annualised basis) already achieved
  • Full year 2021 revenues: 80.5% in the UK, 19.5% internationally

The Helsinn Integrative Care Portfolio (HICP) was acquired on

6 August 2021. This provided a profitable portfolio of products in the area of oncology support.

These oncology market products provide symptomatic relief

for some of the side effects associated with cancer or its treatment. The revenues from these products were affected during the Covid pandemic, when cancer treatments were reduced, but now have significant potential for growth, coming out of that period:

  • Gelclair, for the treatment of oral mucositis, a common side effect of head and neck radiotherapy. Distributed into 34 countries including the UK, and launched in Japan in late 2021.
  • Pomi-T,a polyphenol rich food supplement that reduces the
    inflammation and thus PSA levels in patients with prostate cancer.

Our facility in Italy already manufactured Gelclair for many years, so the acquisition of this brand allowed us to increase the margin capture on this product. Pomi -T has been on the market for much less time than Gelclair, but has already achieved good traction in a short period of time. These products are now fully integrated into the Group, and include good upside opportunities including Gelclair in the USA, Brazil and Canada.

  • Purchase consideration £4.8 million
  • Reported revenues from 7 August 2021 to 31 December 2021 were £1.9 million (full year revenues were £2.9 million, growth of 10.8% over previous year)
  • Full year 2021 revenues: 24.2% in the UK, 75.8% internationally

02

Venture Life Group plc

Annual Report & Accounts 2021

Strategic Report

The Year in Review continued

NEW CHINESE DISTRIBUTOR APPOINTED FOR ORAL CARE BRANDS, POST PERIOD END

On 6 January 2022, we announced our new partner for our oral care brands (Dentyl® and UltraDEX®) in China was Samarkand Group Plc ("Samarkand"), for an exclusive period of 5 years.

Samarkand is a UK based, publicly listed company with expertise in connecting UK brands to the Chinese consumer representing large brands such as Omorovicza, Temple Spa and Philip Kingsley. With operations in Shanghai and London, Samarkand is well placed to emulate the success achieved by both Dentyl® and UltraDEX® in the UK, and the success achieved by the previous partner

in the Chinese market before the pandemic.

Based in London, they have a solid infrastructure in China with over 140 employees and are highly committed to making this partnership work between us.

David Hampstead, CEO Samarkand Group Plc, commented, "We are delighted that Venture Life Group Plc has chosen Samarkand as their new go to market partner for China. Dentyl® and UltraDEX® are market leading brands with established recognition and sales in the China market. Samarkand's on the ground capability in China, combined with our transparent and collaborative approach to working with our brand partners, has once again made us the winning choice for brands."

Report Strategic

Venture Life Group plc

03

Annual Report & Accounts 2021

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Venture Life Group plc published this content on 31 May 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 31 May 2022 11:29:05 UTC.


ę Publicnow 2022
All news about VENTURE LIFE GROUP PLC
12/01FTSE 100 Closes Down 0.2% Amid Drop in Oil-Related Stocks
DJ
12/01Sterling Rises Further Vs Dollar But Depends on US Data
DJ
12/01Venture Life Group Buys HL Healthcare; Shares Surge 19%
MT
12/01AIM WINNERS & LOSERS: Venture Life, Facilities by ADF rise on new b..
AN
12/01Venture Life acquires three new brands with HL Healthcare buy
AN
12/01UK July 2051 Gilt Likely to Outperform Over Next Few Weeks
DJ
12/01FTSE 100 Edges Higher on Powell's Rate Path Signal
DJ
12/01Decline in UK House Prices Has Further to Run, Says Pantheon
DJ
12/01Venture Life Group plc acquired Hl Healthcare Limited for GBP 13 million.
CI
10/10Venture Life : Directorate Changes
PU
More news
Financials
Sales 2022 40,9 M 50,1 M 50,1 M
Net income 2022 1,22 M 1,50 M 1,50 M
Net Debt 2022 0,07 M 0,09 M 0,09 M
P/E ratio 2022 37,0x
Yield 2022 -
Capitalization 43,0 M 52,7 M 52,7 M
EV / Sales 2022 1,05x
EV / Sales 2023 0,79x
Nbr of Employees 145
Free-Float 85,2%
Chart VENTURE LIFE GROUP PLC
Duration : Period :
Venture Life Group plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VENTURE LIFE GROUP PLC
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 34,00 GBX
Average target price 65,00 GBX
Spread / Average Target 91,2%
EPS Revisions
Managers and Directors
Jeremy Anthony Philip Randall Chief Executive Officer & Executive Director
Daniel James Wells Chief Financial Officer & Director
Paul Brian McGreevy Non-Executive Chairman
Sharon Mary Collins Executive Director & Chief Commercial Officer
Gianluca Lodovico Braguti Executive Director & Chief Manufacturing Officer
Sector and Competitors
1st jan.Capi. (M$)
VENTURE LIFE GROUP PLC13.33%53
JOHNSON & JOHNSON4.57%467 679
ELI LILLY AND COMPANY34.07%356 089
ABBVIE INC.20.87%289 331
NOVO NORDISK A/S22.04%285 887
PFIZER, INC.-13.50%285 774